BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Becoming Familiar with an Unknown dialect: My Language Learning Excursion- A hunger for new experiences Narratives: Motivating Travel and Experience
- Instructions to Keep up with Your Traded Teeth for Life span
- The most effective method to Safeguard Your Teeth from Acidic Food varieties and Beverages
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- First Alert: Light snow through this evening
